Description

Doxorubicin Medak (doxorubicin) solution for infusions 2 mg/ml. 5 ml. (10 mg.) №1 vial

Ingredients

Active ingredient: Doxorubicin hydrochloride. Inactive ingredients may include sodium chloride, hydrochloric acid, and water for injections.

Dosage

Dosage: The dosage of Doxorubicin Medak is individualized based on various factors such as body surface area, the condition being treated, and overall health. It is administered intravenously by a healthcare professional.

Indications

Indications: Doxorubicin Medak is indicated for the treatment of various types of cancers including breast cancer, lung cancer, and leukemia. It works by slowing or stopping the growth of cancer cells.

Contraindications

Contraindications: Doxorubicin Medak is contraindicated in patients with severe myelosuppression, severe hepatic impairment, and hypersensitivity to doxorubicin or any of the inactive ingredients.

Directions

Administration: Doxorubicin Medak should only be administered by healthcare professionals experienced in the use of cytotoxic chemotherapy agents. It is given as a slow intravenous infusion to minimize the risk of adverse reactions.

Scientific Evidence

Doxorubicin, the active ingredient in Doxorubicin Medak, has been extensively studied for its efficacy in treating various cancers. Research studies have shown that doxorubicin works by intercalating into DNA strands, inhibiting nucleic acid synthesis and ultimately leading to cell death in cancer cells. Clinical trials have demonstrated the effectiveness of doxorubicin in improving survival rates and reducing tumor size in patients with different types of cancer.

Additional Information

It is important to monitor patients receiving Doxorubicin Medak for signs of cardiotoxicity, myelosuppression, and other potential adverse effects. Close medical supervision is necessary during treatment to ensure the best outcomes for patients. Patients should be informed about the potential side effects of the medication and the need for regular follow-up appointments with their healthcare provider.

Pharmacological Effects: Doxorubicin exerts its antitumor effects by inhibiting topoisomerase II enzyme, leading to DNA damage and cell death. Additionally, it generates free radicals causing oxidative stress, further contributing to its cytotoxic effects.

Comparative Effectiveness: Doxorubicin is considered a cornerstone in the treatment of various cancers and is often used in combination with other chemotherapy agents to enhance its effectiveness. Studies have shown its efficacy in both early-stage and advanced cancers, highlighting its importance in cancer therapy.